Arvinas Inc. is creating a new class of drugs based on protein degradation, which has the potential to open up areas of drug development that were previously closed because of the technical limitations of target inhibition. The company's technology is built on the research of Craig Crews, PhD of Yale University, and has primary application in oncology indications as well as potential in inflammatory, autoimmune and rare diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/26/13 | $15,000,000 | Series A |
5AM Ventures Canaan Partners Connecticut Innovations Elm Street Ventures | undisclosed |
| 10/21/15 | $41,600,000 | Series B |
5AM Ventures Canaan Partners New Leaf Venture Partners OrbiMed Advisors RA Capital | undisclosed |
| 04/04/18 | $55,000,000 | Series C |
5AM Ventures Canaan Partners Deerfield Management Company, L.P. Hillhouse Capital Group New Leaf Venture Partners Nextech Invest  OrbiMed Advisors RA Capital Sirona Capital | undisclosed |
